Novavax, Inc. ( NVAX ) shares are moving higher on Monday. Here’s what you need to know.

What To Know: The company announced on July 2 that it has filed for authorization with Health Canada for its updated 2024-2025 protein-based COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. If approved, this would be the only protein-based COVID-19 vaccine option available in Canada. Novavax's ( NVAX ) updated vaccine targets the JN.1 variant and has shown broad neutralization responses against multiple variant strains, which could make it a significant option for public health programs.

What Else: Novavax ( NVAX ) has also submitted filings with the U.S. FDA and EMA and is working with other regulatory authorities globally to gain authorization for its updated vaccine. These efforts are aligned with the recommendations from the National Advisory Committee on Immunization (NACI), U.S. FDA, EMA and WHO regarding the vaccine composition. The company aims to have the vaccine available in Canada for immediate release post-authorization.

Additionally, Novavax ( NVAX ) has reported an increase in short interest, with 34.36% of the float sold short. Novavax ( NVAX ) shares were trading with a session volume of 9.306 million compared to the 100-day average volume of 16.057 million. Over the past 52 weeks, the stock has ranged from $3.53 to $23.86.

NVAX Price Action: Novavax ( NVAX ) shares were up by 15.6% at $15.17 according to Benzinga pro.

See Also:

Is Telefonica Stock Undervalued Right Now?